Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a new shareholder agreement involving the placement of new H shares under a general mandate. The agreement, which was entered into on June 5, 2025, involves Goldman Sachs and Citigroup as the overall coordinators and placing agents. This placement is part of a strategic move to raise capital, with the new shares to be listed on the Hong Kong Stock Exchange under stock code 6990. The company has clarified that there are no intentions to register these securities under the U.S. Securities Act or conduct a public offering in the United States. Additionally, proposed amendments to the articles of association have been announced.